CATERPILLAR®

March 20, 2008

Dear Doctor,

We are sending this letter to inform you of changes to Caterpillar's benefit plans regarding coverage of the following pharmaceutical products: **Tricor®, Triglide®, Fenoglide®, Lofibra® tabs or caps, and Antara®**.

Fenofibrates are primarily prescribed to lower serum triglycerides and increase HDL-c levels. Multiple brands and generic preparations are available, and they all achieve similar lipid changes because the absorbed level of fenofibrate is similar. It is important to remember that **fenofibrate is fenofibrate**.

The primary variable among the different preparations is the fenofibrate particle size and its associated absorption rate. Products containing larger fenofibrate particles are as effective in higher milligram dosages as products containing smaller fenofibrate particles, which are prescribed in lower milligram dosages. When converting from one product to another, therapeutic equivalence is attainable regardless of differences in particle size. This is because varying particle size has not been shown to alter therapeutic outcomes or the side effect profile.

For example, Tricor brand fenofibrate has evolved from a **micronized** capsule in 1998, to a **microcoated** tablet in 2001, to a **nanocrystal** tablet released in 2004. With each change, the fenofibrate particle size was reduced. As a result, the quantity of fenofibrate needed to achieve similar results is less. The micronized or original version was released as 67 mg and 200 mg fenofibrate capsules. The amount of fenofibrate needed to obtain similar lipid outcomes was reduced to 54 mg and 160 mg tablets with the microcoated formulation. Pharmaceutically and therapeutically equivalent generics ("AB rated") came to the market when the first two Tricor products lost their patents.

Subsequently, Tricor 48 mg and 145 mg nanocrystal fenofibrate tablets have completely replaced both previous Tricor products. This version's patent exclusivity remains in effect. As a result, generic AB rated products for this current version are not yet permitted although the previous FDA-approved generics remain available. These two available generics remain therapeutically equivalent with similar safety profiles.

Substitution with either of these generics is more cumbersome, and the rules differ from the typical AB rated substitution of generics for brands. Substitution of a generic fenofibrate for a brand requires more than simply writing the brand name and adding "may substitute."

Please see the reverse side for prescribing information.

In order for your patient to receive coverage on a generic fenofibrate, the prescription **must** be written as either:

- **Fenofibrate** 54 mg or 160 mg **tablet** (take with food)
  or
- **Fenofibrate** 67 mg, 134 mg or 200 mg **capsule** (take with food)

For patients with renal problems, the FDA recommends the use of lower doses.

Timeline of changes to Caterpillar's prescription drug benefit plans

1. Mid-March – For coverage to be granted, a generic will be required first for all new fenofibrate users:

   54 mg or 160 mg fenofibrate tablets
   or
   67 mg, 134 mg or 200 mg fenofibrate micronized capsules

2. June 1 – Tricor brand fenofibrate will be moved from Preferred (Tier 2) to Non-Preferred (Tier 3) status on both of Caterpillar's formularies (open and closed), making all branded fenofibrates Non-Preferred.

3. August 1 – For current users of branded fenofibrate covered by Caterpillar's open formulary drug plan, a prior authorization will require be required. Prior authorization forms are available on CatHealthBenefits.com under the "For Providers" tab. For current users of branded fenofibrate covered by Caterpillar's closed formulary drug plan, branded fenofibrate will no longer be covered by Caterpillar's prescription drug benefit.

Enclosed is chart of potential therapeutic alternatives that you may find helpful. We recognize the additional work this creates for you but appreciate your cooperation. Your comments and suggestions are welcome.

Sincerely,

Rick Luetkemeyer, M.D.
Caterpillar Inc., Corporate Medical
309-675-4687

Rick Horndasch, M.D.
Caterpillar Inc., Corporate Medical
309-494-0053

References

1. U.S. Food and Drug Administration. Fenofibrate. Electronic Orange Book. Retrieved February 14, 2008 from http://www.fda.gov/cder/ob/
2. Drugs for lipids. Treatment Guidelines from The Medical Letter. 6(66); February 2008.
3. Wan-Chic Tom. Fenofibrate formulations. Pharmacist's Letter/Prescriber's Letter. 21(210909); September 2005.
4. Prescribing information for fenofibrate capsules, micronized (distributed by Global Pharmaceuticals). IMPAX Laboratories Inc., Philadelphia PA; January 2005.
5. Prescribing information for fenofibrate tablets. Ranbaxy Pharmaceuticals Inc., Jacksonville FL; October 2005.
6. Prescribing information for Triglide, Sciele Pharma Inc., France; February 2007.
7. Prescribing information for Tricor. Abbott Laboratories, North Chicago IL; October 2007.
8. Prescribing information for Antara. Oscient Pharmaceuticals, Emeryville CA; July 2007.
9. Prescribing information for Lofibra tablets. GATE Pharmaceuticals, a division of TEVA Pharmaceuticals USA, Sellersville PA; July 2005.
10. Prescribing information for Lofibra capsules. GATE Pharmaceuticals, a division of TEVA Pharmaceuticals USA, Sellersville PA; July 2003.
11. Prescribing information for Lipofen capsules. ProEthic Pharmaceuticals, Montgomery AL; 20 July 2007.
12. Prescribing information for Fenoglide. Sciele Pharma Inc., Atlanta GA; February 2008.